PTC Therapeutics (PTCT) Tops Q2 EPS by 14c

PTC Therapeutics (NASDAQ: PTCT) reported Q2 EPS of ($1.68), $0.14 better than the analyst estimate of ($1.82). Revenue for the quarter came in at $116.7 million versus the consensus estimate of $110.5 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Pfizer lung cancer drug misses survival goal in Phase 3 trial
• Alphabet slides over 6% as AI brain drain and SpaceX slump converge